127 related articles for article (PubMed ID: 12074048)
1. Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2.
Weinreich DM; Rosenberg SA
J Immunother; 2002; 25(2):185-7. PubMed ID: 12074048
[TBL] [Abstract][Full Text] [Related]
2. Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma.
Karp SE
J Immunother; 1998 Jan; 21(1):56-61. PubMed ID: 9456437
[TBL] [Abstract][Full Text] [Related]
3. Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects.
Keilholz U; Scheibenbogen C; Möhler T; Brossart P; Maclachlan D; Geueke AM; Jochim A; Hunstein W
Melanoma Res; 1995 Aug; 5(4):283-7. PubMed ID: 7496166
[TBL] [Abstract][Full Text] [Related]
4. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].
Finck-Seelen ; Lampert R; Brandt L
Anaesthesist; 1996 Dec; 45(12):1171-8. PubMed ID: 9065251
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous low-dose interleukin-2 plus alpha interferon in advanced malignant melanoma.
de Braud F; Biganzoli L; Bajetta E; Colleoni M; Zampino MG
Tumori; 1993 Jun; 79(3):187-90. PubMed ID: 8236501
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Linehan WM; Seipp C; Calabro S; Karp SE; Sherry RM; Steinberg S; White DE
J Clin Oncol; 1989 Dec; 7(12):1863-74. PubMed ID: 2685181
[TBL] [Abstract][Full Text] [Related]
8. Does continuous-infusion interleukin-2 increase survival in metastatic melanoma?
Dillman RO; O'Connor AA; Simpson L; Barth NM; VanderMolen LA; Vanderplas P
Am J Clin Oncol; 2003 Apr; 26(2):141-5. PubMed ID: 12714884
[TBL] [Abstract][Full Text] [Related]
9. Initial clinical response predicts outcome and is associated with dose schedule in metastatic melanoma and renal cell carcinoma patients treated with high-dose interleukin 2.
Spanknebel K; Cheung KY; Stoutenburg J; Hurst-Wicker K; Hesdorffer C; Deraffele G; Kaufman HL
Ann Surg Oncol; 2005 May; 12(5):381-90. PubMed ID: 15915372
[TBL] [Abstract][Full Text] [Related]
10. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
Rosenberg SA; Yang JC; White DE; Steinberg SM
Ann Surg; 1998 Sep; 228(3):307-19. PubMed ID: 9742914
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
12. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
13. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
Dutcher JP
Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):4-10. PubMed ID: 12469934
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Smith FO; Downey SG; Klapper JA; Yang JC; Sherry RM; Royal RE; Kammula US; Hughes MS; Restifo NP; Levy CL; White DE; Steinberg SM; Rosenberg SA
Clin Cancer Res; 2008 Sep; 14(17):5610-8. PubMed ID: 18765555
[TBL] [Abstract][Full Text] [Related]
17. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
Eton O; Talpaz M; Lee KH; Rothberg JM; Brell JM; Benjamin RS
Cancer; 1996 Mar; 77(5):893-9. PubMed ID: 8608480
[TBL] [Abstract][Full Text] [Related]
19. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
20. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]